Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ONTIME |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This purpose of the study was to evaluate the earliest time to onset of action in adults with erectile dysfunction (often called impotence). In this study vardenafil has been compared to placebo. Patients were asked to fill in questionnaires and a diary in which they filled in details about attempts at sexual activity during study period. Patients received also a stopwatch to record the time of onset of erection. Stopwatch should be started immediately prior to initiating sexual activity and stopped when an erection perceived to be adequate for penetration was obtained.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Experimental |
| |
| Arm 2 | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Levitra (Vardenafil, BAY38-9456) | Drug | Vardenafil 10 mg and 20 mg orally once a day as needed |
| |
| Measure | Description | Time Frame |
|---|---|---|
| - Earliest elapsed time from dosing to attainment of an erection perceived to be adequate for penetration leading to completion of successful intercourse as measured by Sexual Encounter Profile Question 3 (SEP 3) | First four doses with successful intercourse |
| Measure | Description | Time Frame |
|---|---|---|
| - Earliest elapsed time from dosing to attainment of an erection perceived to be adequate for penetration as measured by Sexual Encounter Profile Question 2 (SEP 2). | among the first four doses | |
| - The erectile function (EF) domain score of the International Index of Erectile Function (IIEF) calculated as the sum of scores from Questions 1-5 and 15 at Week 4 as well as all other IIEF factor subscores. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Phoenix | Arizona | 85023 | United States | |||
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Matching Placebo |
|
| among the first four doses |
| - Responder time to onset, where onset is time from dosing to attainment of an erection perceived to be adequate for penetration. | among the first four doses |
| - Other diary questions | among the first four doses |
| - Safety and tolerability | within the study duration |
| Beverly Hills |
| California |
| 90212 |
| United States |
| San Bernardino | California | 92404 | United States |
| Aurora | Colorado | 80012 | United States |
| Trumbull | Connecticut | 06611 | United States |
| Aventura | Florida | 33180 | United States |
| Jacksonville | Florida | 32257 | United States |
| Pembroke Pines | Florida | 33024 | United States |
| Lawrenceville | New Jersey | 08648 | United States |
| New York | New York | 10016 | United States |
| Charlotte | North Carolina | 28209 | United States |
| Wilmington | North Carolina | 28401 | United States |
| Calgary | Alberta | T3G 3J9 | Canada |
| Winnipeg | Manitoba | R3T 5J3 | Canada |
| Saint John | New Brunswick | E2L 3J8 | Canada |
| Kentville | Nova Scotia | B4N 4K9 | Canada |
| Barrie | Ontario | L4M 4S5 | Canada |
| Toronto | Ontario | M4C 3E7 | Canada |
| Montreal | Quebec | H1T 2M4 | Canada |
| Sherbrooke | Quebec | J1H 5N4 | Canada |
| Carpentras | 84200 | France |
| Lille | 59000 | France |
| Lyon | 69000 | France |
| Lyon | 69437 | France |
| Marseille | 13275 | France |
| Montpellier | 34000 | France |
| Nîmes | 30000 | France |
| Paris | 75015 | France |
| Garmisch-Partenkirchen | Bavaria | 82467 | Germany |
| München | Bavaria | 80333 | Germany |
| München | Bavaria | 81925 | Germany |
| Hamburg | Free and Hanseatic City of Hamburg | 20354 | Germany |
| Marburg | Hesse | 35039 | Germany |
| Hanover | Lower Saxony | 30625 | Germany |
| Osnabrück | Lower Saxony | 49076 | Germany |
| Westerstede | Lower Saxony | 26655 | Germany |
| Düsseldorf | North Rhine-Westphalia | 40210 | Germany |
| Mönchengladbach | North Rhine-Westphalia | 41061 | Germany |
| Niederkassel | North Rhine-Westphalia | 53859 | Germany |
| Leipzig | Saxony | 04105 | Germany |
| Halle | Saxony-Anhalt | 06097 | Germany |
| Milan | 20132 | Italy |
| Milan | 20142 | Italy |
| Modena | 41100 | Italy |
| Naples | 80131 | Italy |
| Padova | 35128 | Italy |
| Amsterdam | 1061 AE | Netherlands |
| Nijmegen | 6525 GA | Netherlands |
| Roermond | 6043 CV | Netherlands |
| The Hague | 2512 VA | Netherlands |
| Utrecht | 3514 AB | Netherlands |
| Moelv | 2390 | Norway |
| Oslo | 0272 | Norway |
| Sarpsborg | 1700 | Norway |
| Trondheim | 7006 | Norway |
| Warsaw | Poland | 04-749 | Poland |
| Kościerzyna | 83-400 | Poland |
| Lodz | 91-425 | Poland |
| Poznan | 61-701 | Poland |
| Warsaw | 01-059 | Poland |
| Wroclaw | 54-144 | Poland |
| Badalona | Barcelona | 08916 | Spain |
| Barcelona | Barcelona | 08003 | Spain |
| L'Hospitalet de Llobregat | Barcelona | 08907 | Spain |
| Galdakao | Bizkaia | 48960 | Spain |
| Castellon | Castellón de La Plana | 12004 | Spain |
| Barcelona | Catalonia | 08025 | Spain |
| Madrid | Madrid | 28040 | Spain |
| Zaragoza | Zaragoza | 50009 | Spain |
| Borås | 503 32 | Sweden |
| Gothenburg | 412 59 | Sweden |
| Skövde | 541 30 | Sweden |
| Stockholm | 171 76 | Sweden |
| Bristol | Avon | BS10 5NB | United Kingdom |
| Bristol | Avon | BS2 8HW | United Kingdom |
| ID | Term |
|---|---|
| D007172 | Erectile Dysfunction |
| ID | Term |
|---|---|
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D012735 | Sexual Dysfunction, Physiological |
| D052801 | Male Urogenital Diseases |
| D020018 | Sexual Dysfunctions, Psychological |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069058 | Vardenafil Dihydrochloride |
| ID | Term |
|---|---|
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D010879 | Piperazines |
Not provided
Not provided